France was studied in detail in a report produced by the Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute). The report surveyed measures for promoting the rational use of medicines in the 27 EU member states.
France’s rational use of medicines
Home/Reports | Posted 25/03/2011 0 Post your comment
Monitoring of pharmaceutical expenditure and consumption in France is carried out by the social health insurance and the French medicines agency, Agence francaise de sécurité sanitaire des produits de santé (AFSSAPS).
AFSSAPS contains a department, the National Observatory for Prescriptions and Consumption of Medicines, which produces analysis reports on the development of consumption in specific pharmaceutical groups.
A typical feature of the French system is agreements between the social health insurance and actors, e.g. with pharmacists to reach certain generic substitution targets and with doctors to prescribe cost-effectively. In 2009, the social health insurance started to make individual contracts with doctors, in addition to the existing framework agreement with the doctors’ associations. Representatives of the social health insurance also visit prescribing doctors to inform and advice them about measures for more rational use of medicines.
Generic substitution is allowed, but not obligatory in France. Pharmacists are granted a financial incentive to encourage them to substitute brand-name drugs for generic ones. When dispensing a generic, they receive the same amount of remuneration as they would have received for the original product.
Information campaigns targeted at the general public are regularly organised by the French social health insurance.
Acknowledgement
This article is published with permission of the Gesundheit Österreich GmbH (GÖG)/Austrian Health Institute.
We gratefully acknowledge the support from Dr Sabine Vogler of Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG – Austrian Health Institute) to GaBI Online.
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Related articles
The EU and rational use of medicines
Survey on rational use of medicines in 27 EU Members States
The Netherlands and rational use of medicines
Italy’s rational use of medicines
Germany’s rational use of medicines
Rational use of medicines in Denmark
Promoting rational use of medicines in Europe
Reference
Vogler S, Schmickl B. Rational use of medicines in Europe. Gesundheit Österreich GmbH / Österreichisches Bundesinstitut für Gesundheitswesen (GÖG/ÖBIG). February 2010.
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Comments (0)
Post your comment